EXACT SCIENCES

We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment.

Second-quarter 2023 earnings call

August 1, 2023

Safe harbor and non-GAAP disclosures

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services and their impact on patients; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.

In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management uses non-GAAP financial measures to establish budgets, manage the Company's business, and set incentive and compensation arrangements. The company presents EBITDA, adjusted EBITDA, non-GAAP gross margin, non-GAAP gross profit, core revenue, and free cash flow. This presentation includes certain of these measures. Please refer to our second-quarter 2023 earnings release for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures. Information reconciling forward-looking non-GAAP measures to U.S. GAAP measures is not available without unreasonable effort due to the inherent uncertainty of the financial impact of items such as stock-based compensation, and acquisition and integration costs including gains and losses on contingent consideration liabilities that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally, management does not forecast many of the excluded items for internal use.

Delivering innovative tests that help prevent cancer, detect it earlier, and guide treatment to patients globally

OUR TEAM

500 R&D team members

1,200 person commercial team

OUR FLAGSHIP TESTS

IM+ people tested in 2Q23

cologuard®

oncotype DX®

120 country presence

oncoExTra[™]

Q2 RESULTS

Record total revenue of \$622M, 24% core revenue growth


Adjusted EBITDA of \$67M and free cash flow of \$66M

Raising revenue guidance by \$54M and **adjusted EBITDA guidance** by \$63M

Core revenue excludes COVID testing revenue, the divested Oncotype DX prostate test, and the impact of foreign exchange Guidance increase refers to midpoint of updated 2023 guidance range Please refer to our second-guarter 2023 earnings release at exactsciences.com for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures

EXACT SCIENCES

Core revenue grew 24% in 2Q23



Core revenue excludes COVID testing revenue, the divested Oncotype DX prostate test, and the impact of foreign exchange

Precision Oncology revenue grew 7% excluding the divested Oncotype DX prostate test and a \$0.2M FX benefit

Please refer to our second-quarter 2023 earnings release at exactsciences.com for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures

EXACT SCIENCES

Updated 2023 guidance

	<u>Prior guidance</u>	<u>August 1 update</u>	<u>Δ at midpoint</u>			
Total revenue	\$2.380 - 2.420B	\$2.441 - 2.466B	+\$54M			
Screening	\$1.770 - 1.795B	\$1.820 - 1.835B	+\$45M			
Precision Oncology	\$605 - 620M	\$615 - 625M	+\$8M			
COVID testing	~ \$5 M	\$6M	+\$1M			
Adj. EBITDA	\$100 - 125M	\$170 - 180M	+\$63M			
CapEx	~\$120M	~\$120M	-			

Exact Sciences guidance provided August 1, 2023

Please refer to our second-quarter 2023 earnings release at exactsciences.com for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures

EXACT SCIENCES

Raising the bar in non-invasive screening

DeeP-C



87% specificity including nonadvanced findings

90%

specificity including no findings

92%

cancer sensitivity

69%

high-grade dysplasia sensitivity

42%

advanced precancer sensitivity

91% specificity including nonadvanced findings

93% specificity including no findings

94%

cancer sensitivity

75%

high-grade dysplasia sensitivity

43%

advanced precancer sensitivity


Source: Exact Sciences internal data

BLUE-C



Source: Imperiale TF et al., N Engl J Med (2014) **EXACT SCIENCES**

Expanding Oncotype DX impact with coverage in Japan



90K

women diagnosed with breast cancer every year

Regulatory approval

, Reimbursement decision

Sep. Full2023 launch

Source: World Health Organization, Exact Sciences estimates

Progress in our molecular residual disease and multi-cancer early-detection programs



Expanded breadth of mutations

Attractive cost profile

Full readout early 2024

Partial readout fall 2023



We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment.

EXACT SCIENCES

EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data)

	Th	ree Months End	led June 30,	Six Months Ended June 30,				
		2023	2022	2023	2022			
Revenue	\$	622,093 \$	521,640 \$	1,224,543 \$	1,008,211			
Operating expenses								
Cost of sales (exclusive of amortization of acquired intangible assets)		156,991	144,600	313,857	279,305			
Research and development		104,095	106,083	199,514	208,331			
Sales and marketing		176,490	215,922	363,454	448,103			
General and administrative		237,965	181,672	455,260	351,442			
Amortization of acquired intangible assets		22,929	26,356	45,857	51,010			
Impairment of long-lived assets		552	6,591	621	6,591			
Total operating expenses		699,022	681,224	1,378,563	1,344,782			
Loss from operations		(76,929)	(159,584)	(154,020)	(336,571)			
Other income (expense)								
Investment income (loss), net		4,828	(3,719)	5,318	(5,206)			
Interest expense		(7,818)	(4,511)	(3,711)	(8,989)			
Total other income (expense)		(2,990)	(8,230)	1,607	(14,195)			
Net loss before tax		(79,919)	(167,814)	(152,413)	(350,766)			
Income tax benefit (expense)		(1,107)	1,751	(2,764)	3,766			
Net loss	\$	(81,026) \$	(166,063) \$	(155,177) \$	(347,000)			
Net loss per share—basic and diluted	\$	(0.45) \$	(0.94) \$	(0.87) \$	(1.98)			
The ross per share—basic and unuted	Ψ	<u>(U.T.)</u> ø	(0.74) 3	(0.07) 5	(1.98)			
Weighted average common shares outstanding—basic and diluted		180,204	176,364	179,393	175,396			

EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands)

	June 30, 2023		Decem	ber 31, 2022
Assets				
Cash and cash equivalents	\$	604,363	\$	242,493
Marketable securities		171,349		389,564
Accounts receivable, net		178,317		158,043
Inventory		130,770		118,259
Prepaid expenses and other current assets		89,129		73,898
Property, plant and equipment, net		686,602		684,756
Operating lease right-of-use assets		148,690		167,003
Goodwill		2,346,248		2,346,040
Intangible assets, net		1,910,559		1,956,240
Other long-term assets, net		89,536		90,577
Total assets	\$	6,355,563	\$	6,226,873
Liabilities and stockholders' equity				
Current liabilities	\$	488,057	\$	412,747
Convertible notes, net		2,311,567		2,186,106
Long-term debt, less current portion				50,000
Other long-term liabilities		330,816		352,459
Operating lease liabilities, less current portion		168,501		182,399
Total stockholders' equity		3,056,622		3,043,162
Total liabilities and stockholders' equity	\$	6,355,563	\$	6,226,873

EXACT SCIENCES CORPORATION

Selected Unaudited Financial Information

Reconciliation of Core Revenue

(Amounts in thousands)

GAAP

	Three Months Ended June 30,					
	2023		2022	% Change		
Screening	\$ 462,787	\$	353,894	31 %		
Precision Oncology	157,174		153,995	2 %		
COVID-19 Testing	2,132		13,751	(84)%		
Total	\$ 622,093	\$	521,640	19 %		

Non-GAAP Three Months Ended June 30, **Foreign Currency** 2023 (1) 2022 (1) % Change Impact (2) % Change⁽³⁾ Core Revenue ⁽³⁾ Screening \$ 462,787 \$ 353,894 31 % \$ \$ 462,787 31 % Precision Oncology 154,884 144,450 7 % (198)154,686 7 % 617,671 \$ 24 % \$ (198) \$ 24 % \$ 498,344 617,473 Total

	GAAP					
	Six Months Ended June 30,					
	2023 2022			% Change		
Screening	\$	905,982	\$	660,416	37 %	
Precision Oncology		312,606		306,615	2 %	
COVID-19 Testing		5,955		41,180	(86)%	
Total	\$	1,224,543	\$	1,008,211	21 %	

]	Non-GAAP						
	Six	Mon	ths Ended June	30,					
	2023 (1)		2022 ⁽¹⁾	% Change	Fo	reign Currency Impact ⁽²⁾	Co	re Revenue ⁽³⁾	% Change ⁽³⁾
Screening	\$ 905,982	\$	660,416	37 %	\$		\$	905,982	37 %
Precision Oncology	308,275		288,102	7 %		1,094		309,369	7 %
Total	\$ 1,214,257	\$	948,518	28 %	\$	1,094	\$	1,215,351	28 %

EXACT SCIENCES

For associated footnotes, please refer to the table in the second-quarter 2023 results press release labeled Reconciliation of Core Revenue

EXACT SCIENCES CORPORATION

Selected Unaudited Financial Information

Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

(Amounts in thousands)

	Т	hree Months	End	ed June 30,		l June 30,		
		2023		2022		2023		2022
Revenue	\$	622,093	\$	521,640	\$	1,224,543	\$	1,008,211
Cost of sales (exclusive of amortization of acquired intangible assets)		156,991		144,600		313,857		279,305
Amortization of acquired intangible assets (1)		20,718		22,477		41,435		44,954
Gross profit	\$	444,384	\$	354,563	\$	869,251	\$	683,952
Gross margin		71 %		68 %		71 %		68 %
Amortization of acquired intangible assets (1)		20,718		22,477		41,435		44,954
Non-GAAP gross profit	\$	465,102	\$	377,040	\$	910,686	\$	728,906
Non-GAAP gross margin		75 %		72 %		74 %		72 %

For associated footnote, please refer to the table in the second-quarter 2023 results press release labeled Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands)

	Three Months Ended June 30,			Six 1	Months E	nded June 30,		
(In thousands)	2023		2022		2023			2022
Net loss	\$	(81,026)	\$	(166,063)	6 (1	155,177)	\$	(347,000)
Interest expense ⁽¹⁾		7,818		4,511		3,711		8,989
Depreciation and amortization		50,439		51,861		100,182		99,508
Income tax (benefit) expense		1,107		(1,751)		2,764		(3,766)
EBITDA	\$	(21,662)	\$	(111,442)	5	(48,520)	\$	(242,269)
Stock-based compensation (2)		70,766		64,494		132,663		129,975
Investment loss (income)		(4,828)		3,719		(5,318)		5,206
Acquisition and integration costs ⁽³⁾		4,773		(23,742)		(3,751)		(49,703)
Reduction-in-force severance ⁽⁴⁾				14,613		907		14,613
Impairment of long-lived assets (5)		552		6,591		621		6,591
Legal settlement ⁽⁶⁾		17,250				36,186		_
Adjusted EBITDA	\$	66,851	\$	(45,767)	5	112,788	\$	(135,587)

For associated footnotes, please refer to the table in the second-quarter 2023 results press release labeled EBITDA and Adjusted EBITDA Reconciliations

EXACT SCIENCES CORPORATION

Selected Unaudited Financial Information

Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow

(Amounts in thousands)

	Three Months E	nded June 30,	Six Months End	ded June 30,
(In thousands)	2023	2022	2023	2022
Net cash used in operating activities	100,424	(60,916)	62,209	(234,670)
Net cash provided by investing activities	66,474	21,659	149,415	67,220
Net cash provided by financing activities	16,041	63,412	149,637	66,147
Effects of exchange rate changes on cash and cash equivalents	59	(510)	609	(747)
Net increase (decrease) in cash, cash equivalents and restricted cash	182,998	23,645	361,870	(102,050)
Cash, cash equivalents and restricted cash, beginning of period	421,662	190,073	242,790	315,768
Cash, cash equivalents and restricted cash, end of period	604,660	213,718	604,660	213,718
Reconciliation of free cash flow:				
Cash used by operating activities	100,424	(60,916)	62,209	(234,670)
Capital expenditures	(34,721)	(63,326)	(64,081)	(96,949)
Free cash flow	65,703	(124,242)	(1,872)	(331,619)